1. Home
  2. ITOC vs SNGX Comparison

ITOC vs SNGX Comparison

Compare ITOC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITOC

iTonic Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$0.33

Market Cap

5.6M

Sector

N/A

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.37

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITOC
SNGX
Founded
1998
1987
Country
China
United States
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.6M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
ITOC
SNGX
Price
$0.33
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
152.3K
586.9K
Earning Date
03-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.28
52 Week High
$1.15
$6.23

Technical Indicators

Market Signals
Indicator
ITOC
SNGX
Relative Strength Index (RSI) 48.94 37.48
Support Level $0.28 $0.28
Resistance Level $0.34 $0.41
Average True Range (ATR) 0.02 0.02
MACD -0.00 0.01
Stochastic Oscillator 25.31 15.68

Price Performance

Historical Comparison
ITOC
SNGX

About ITOC iTonic Holdings Ltd Class A Ordinary Shares

iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: